Leerink Swann Reiterates Outperform on Insmed Following MEDACorp KOL Checks
August 28, 2013 at 11:52 AM EDT
In a report published Wednesday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating and $22.00 price target on Insmed (NASDAQ: INSM ). In the report, Leerink Swann noted, “With potentially pivotal but simultaneously proof-of-concept Arikace non-tuberculous mycobacteria (NTM) data imminent in 1Q:14, we have performed additional MEDACorp KOL
